{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:20:54Z","timestamp":1792686054570,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003420.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000}}],"reference-count":65,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003420.pub4","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T10:51:00Z","timestamp":1263811860000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Antithyroid drug regimen for treating Graves' hyperthyroidism"],"prefix":"10.1002","volume":"2010","author":[{"given":"Prakash","family":"Abraham","sequence":"first","affiliation":[{"name":"Aberdeen Royal Infirmary, NHS Grampian; Endocrinology (Ward 28); Foresterhill Aberdeen Scotland UK AB25 2ZN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Avenell","sequence":"additional","affiliation":[{"name":"University of Aberdeen; Health Services Research Unit; Foresterhill Aberdeen UK AB25 2ZD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C","family":"McGeoch","sequence":"additional","affiliation":[{"name":"NHS Grampian; Department of Diabetes and Endocrinology; Foresterhill Aberdeen Aberdeenshire UK AB25 2ZN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise F","family":"Clark","sequence":"additional","affiliation":[{"name":"Aberdeen Royal Infirmary; Department of Diabetes and Endocrinology; Foresterhill Aberdeen UK AB25 2ZN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Bevan","sequence":"additional","affiliation":[{"name":"Aberdeen Royal Infirmary; Endocrinology (Ward 27\/28; Aberdeen UK AB25 2ZN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"10.1002\/14651858.CD003420.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-70-3-675","article-title":"Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration","volume":"70","author":"Allannic","year":"1990","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"14","key":"10.1002\/14651858.CD003420.pub4-BIB0002|cit2","first-page":"649","article-title":"Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy","volume":"20","author":"Allannic","year":"1991","journal-title":"Presse Medicale"},{"issue":"4","key":"10.1002\/14651858.CD003420.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs","volume":"49","author":"Benker","year":"1998","journal-title":"Clinical Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0004|cit4","first-page":"1516","article-title":"A prospective randomized trial of antithyroid drug dose in Graves' disease therap","volume":"76","author":"Reinwein","year":"1993","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD003420.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.curtheres.2008.08.004","article-title":"Comparison of methimazole\/hydrocortisone ointment with oral methimazole in patients with graves disease: A prospective, randomized, open-label, parallel-group, 18-month study","volume":"69","author":"Chen","year":"August 2008","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.1992.tb02269.x","article-title":"Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease","volume":"36","author":"Cho","year":"1992","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0008|cit7","unstructured":"Edmonds CJ Personal Communication"},{"issue":"2","key":"10.1002\/14651858.CD003420.pub4-BIB0007|cit8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1530\/eje.0.1310120","article-title":"Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose","volume":"131","author":"Edmonds","year":"1994","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/BF03348811","article-title":"Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission","volume":"15","author":"Garcia-Mayor","year":"1992","journal-title":"Journal of Endocrinology and Investigation"},{"issue":"4","key":"10.1002\/14651858.CD003420.pub4-BIB0011|cit10","first-page":"A296","article-title":"Clinical epidemiology of Basedow's disease in Belgium","volume":"21","author":"Glinoer","year":"2000","journal-title":"Revue Medicale de Bruxelles"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0010|cit11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","article-title":"Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study","volume":"144","author":"Glinoer","year":"2001","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD003420.pub4-BIB0012|cit12","first-page":"11","article-title":"Recurrence of Graves-Basedow disease: the influence of treatment schedule","volume":"104","author":"Goni Iriarte","year":"1995","journal-title":"Medicina Clinica"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1046\/j.1365-2265.1998.00446.x","article-title":"A randomized trial of short-term treatment of Graves' disease with high- dose carbimazole plus thyroxine versus low-dose carbimazole","volume":"48","author":"Grebe","year":"1998","journal-title":"Clinical Endocrinology"},{"issue":"14","key":"10.1002\/14651858.CD003420.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","article-title":"Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism","volume":"324","author":"Hashizume","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD003420.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/105072502321085225","article-title":"Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine","volume":"12","author":"Hoermann","year":"2002","journal-title":"Thyroid"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00108-003-0876-x","article-title":"Drug treatment of immune hyperthyroidism (Basedow disease). Patient selection, long-term follow-up and prevention of recurrence","volume":"44","author":"Quadbeck","year":"2003","journal-title":"Internist"},{"issue":"8","key":"10.1002\/14651858.CD003420.pub4-BIB0017|cit17","first-page":"868","article-title":"The value of early immunosuppressive therapy in the prevention of Graves' disease complications","volume":"61","author":"Huszno","year":"2004","journal-title":"Przeglad Lekarski"},{"issue":"2","key":"10.1002\/14651858.CD003420.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2796.1995.tb00914.x","article-title":"Short-term treatment of Graves' disease with methimazole in high versus low doses","volume":"238","author":"Jorde","year":"1995","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003420.pub4-BIB0019|cit19","first-page":"11","article-title":"Treatment of Basedow disease with synthetic antithyroid drugs. Evaluation of the dose on the efficacy of the long term treatment","volume":"55","author":"Leclere","year":"1994","journal-title":"Annales d'Endocrinologie"},{"issue":"8","key":"10.1002\/14651858.CD003420.pub4-BIB0020|cit20","first-page":"2410","article-title":"Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?","volume":"82","author":"Lucas","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/BF03348195","article-title":"T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy","volume":"26","author":"Mastorakos","year":"2003","journal-title":"Journal of Endocrinological Investigation"},{"issue":"1","key":"10.1002\/14651858.CD003420.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2265.1999.00629.x","article-title":"Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment","volume":"50","author":"Maugendre","year":"1999","journal-title":"Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD003420.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJM199601253340403","article-title":"Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug","volume":"334","author":"McIver","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease","volume":"147","author":"Nedrebo","year":"2002","journal-title":"European Journal of Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.ten.0000249137.35809.b3","article-title":"Antithyroid drugs for the treatment of graves disease: A randomized clinical trial","volume":"16","author":"Peixoto","year":"2006","journal-title":"Endocrinologist"},{"issue":"1","key":"10.1002\/14651858.CD003420.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/eje.0.1360081","article-title":"Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume","volume":"136","author":"Pfeilschifter","year":"1997","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD003420.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1420117","article-title":"Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine","volume":"142","author":"Raber","year":"2000","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0028|cit28","first-page":"814","article-title":"Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease","volume":"83","author":"Rittmaster","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7Suppl","key":"10.1002\/14651858.CD003420.pub4-BIB0029|cit29","first-page":"A71","article-title":"Effects of antithyroid drugs alone and plus L-thyroxine on the relapse of Graves disease","volume":"23","author":"Tuncel","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0030|cit30","first-page":"337","article-title":"Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse","volume":"87","author":"Weetman","year":"1994","journal-title":"Quarterly Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/qjmed\/89.5.381","article-title":"Do higher doses of carbimazole improve remission in Graves' disease?","volume":"89","author":"Wilson","year":"1996","journal-title":"Quarterly Journal of Medicine"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0032|cit32","first-page":"1124","article-title":"Improvement of the prognosis of Basedow's disease by using high doses of carbimazole","volume":"17","author":"Duprey","year":"1988","journal-title":"Presse Medicale"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in graves' disease: A controlled pilot study.","volume":"92","author":"Fassi","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD003420.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/thy.1996.6.29","article-title":"Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease","volume":"6","author":"Escobar-Morreale","year":"1996","journal-title":"Thyroid"},{"issue":"23","key":"10.1002\/14651858.CD003420.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.1978.03280500053019","article-title":"Prospective randomized comparison of propylthiouracil","volume":"239","author":"Gwinup","year":"1978","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF03348036","article-title":"Role of colestipol in the treatment of hyperthyroidism","volume":"21","author":"Hagag","year":"1998","journal-title":"Journal of Endocrinological Investigation"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2265.2004.02032.x","article-title":"Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism","volume":"60","author":"He","year":"2004","journal-title":"Clinical endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves' disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2265.2001.01239.x","article-title":"Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism","volume":"54","author":"Homsanit","year":"2001","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2796.1996.489827000.x","article-title":"Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease","volume":"239","author":"Kallner","year":"1996","journal-title":"Journal of Internal Medicine"},{"issue":"7960","key":"10.1002\/14651858.CD003420.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(76)90414-1","article-title":"Lithium carbonate in the treatment of thyrotoxicosis. A controlled trial","volume":"1","author":"Kristensen","year":"1976","journal-title":"The Lancet"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1507\/endocrj.52.735","article-title":"Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease","volume":"52","author":"Kubota","year":"2005","journal-title":"Endocrine Journal"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0043|cit43","first-page":"139","article-title":"Treatment of hyperthyroidism with a small single daily dose of methimazole","volume":"119","author":"Mashio","year":"1988","journal-title":"Acta Endocrinologica"},{"issue":"2-3","key":"10.1002\/14651858.CD003420.pub4-BIB0044|cit44","first-page":"257","article-title":"Effect of therapy duration and low and highly dosed thiamazole treatment in Basedow's-Graves' disease","volume":"97","author":"Meng","year":"1991","journal-title":"Experimental Clinical Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03348132","article-title":"Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages","volume":"10","author":"Messina","year":"1987","journal-title":"Journal of Endocrinological Investigation"},{"issue":"6","key":"10.1002\/14651858.CD003420.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/jc.2006-2135","article-title":"Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease","volume":"92","author":"Nakamura","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD003420.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/00007611-199509000-00018","article-title":"\u00a0 Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism","volume":"88","author":"Nicholas","year":"1995","journal-title":"Southern Medical Journal"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.1988.tb01226.x","article-title":"Higher than conventional doses of carbimazole in the treatment of thyrotoxicosis","volume":"29","author":"O'Malley","year":"1988","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1365-2265.1996.00800.x","article-title":"A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism","volume":"45","author":"Page","year":"1996","journal-title":"Clinical Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1998.00466.x","article-title":"TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates","volume":"48","author":"Pujol","year":"1998","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD003420.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-57-3-563","article-title":"Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism","volume":"57","author":"Romaldini","year":"1983","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD003420.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study","volume":"156","author":"Salvi","year":"2007","journal-title":"European Journal of Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD003420.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.biopha.2007.01.001","article-title":"\u00a0Combination therapy of chloroquine and methimazole in Graves' disease: a pilot randomized controlled trial","volume":"61","author":"Soltani","year":"2007","journal-title":"Biomedicine & pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0054|cit54","first-page":"1481","article-title":"Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients","volume":"80","author":"Tamai","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD003420.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2265.2005.02249.x","article-title":"The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism","volume":"62","author":"Tsai","year":"2005","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cccn.2003.10.028","article-title":"Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium","volume":"341","author":"Vrca","year":"2004","journal-title":"Clinica Chimica Acta"},{"issue":"229","key":"10.1002\/14651858.CD003420.pub4-BIB0057|cit57","first-page":"409","article-title":"Prediction of outcome in Graves' disease after carbimazole treatment","volume":"59","author":"Weetman","year":"1986","journal-title":"Quarterly Journal of Medicine"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educational and Psychological Measurement"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Systematic reviews: Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"issue":"24","key":"10.1002\/14651858.CD003420.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJM199406163302407","article-title":"The management of hyperthyroidism","volume":"330","author":"Franklyn","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD003420.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2265.1998.00558.x","article-title":"Controversies in the management of Graves' disease","volume":"49","author":"Leech","year":"1998","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD003420.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0950-351X(97)80753-7","article-title":"Thyroxine suppression therapy in Graves' disease","volume":"11","author":"Toft","year":"1997","journal-title":"Bailliere's Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD003420.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A systematic review of drug therapy for Graves' hyperthyroidism","volume":"153","author":"Abraham","year":"2005","journal-title":"European Journal of Endocrinology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003420.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:16:38Z","timestamp":1754324198000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003420.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003420.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}